Pfizer Chairman Albert Bourla announced this, according to the New York Times. By the end of the year, the company will have produced enough doses to immunize 15 to 20 million people.
Pfizer, which developed the vaccine with German pharmaceutical manufacturer BioNTech, has released just a few details of its clinical trial, which was based on the first formal review of data by a group of outside experts. The company said the analysis found the vaccine to be more than 90 percent effective in preventing illness among study volunteers who had no evidence of a previous coronavirus infection. No serious safety issues were noted, the company said.
Pfizer plans to apply for emergency authorization of the two-dose vaccine from the Food and Drug Administration later this month, after collecting safety data for two months, as recommended by law. By the end of the year, the company will have produced enough doses to immunize 15 to 20 million people.
The trial is expected to continue until 164 people in the 44,000-person trial have developed antibodies against Covid-19, and will also assess how well it protects against developing severe forms of the disease and how well the vaccine protects people. that have already been infected. of the coronavirus. Half of the participants received two doses of the vaccine and the other half received a placebo.
Berlin: “We will act in a European way on the vaccine” – “We want to act in a European way and not following a national line.” German Health Minister Jens Spahn said this at a press conference in Berlin, commenting on the news of the Biontech data release. “We have to come up with a voluntary vaccine,” Spahn reiterated as well. “When asked what dosage amounts and when will they be available, we are still unable to answer,” he added.
Trump: “The vaccine is coming, great news!” – “Stock goes up, the vaccine will arrive soon. 90% effectiveness report. Good news!” Donald Trump writes on Twitter commenting on Pfizer’s announcement.
